Pulsenmore Ltd. has developed pioneering portable ultrasound devices designed for home use, uniquely combining proprietary hardware with telehealth-enabled software. The company’s revenues reached approximately $12.5 million in 2025, driven mainly by strong partnerships with Israeli health organizations and recent FDA clearance enabling U.S. market expansion. Despite posting a net loss of $4.97 million in 2025, Pulsenmore’s robust patent portfolio, diversified product pipeline, and strategic geographic growth initiatives set the stage for further commercial traction. Key challenges remain around regulatory compliance, reimbursement dynamics, and scaling operational capabilities.